{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:12:46Z","timestamp":1779167566287,"version":"3.51.4"},"reference-count":52,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prophylaxis is the standard of care for patients with severe hemophilia, patients with moderate hemophilia, or those with another congenital bleeding disorder that is associated with a severe bleeding phenotype and\/or a high risk of spontaneous life-threatening bleeding. Patients with nonsevere hemophilia (factor VIII [FVIII] \u2265 1%) may also have a bleeding phenotype that requires prophylaxis. To date, however, there are no clear criteria as to when prophylaxis is indicated in these patients. Also, the term \u201csevere bleeding phenotype (SBPT)\u201d is neither included in the definitions of the International Society on Thrombosis and Haemostasis (ISTH) nor specified in the World Federation of Hemophilia (WFH) guidelines. Based on our personal experience and available evidence, we propose the criteria we use to define an SBPT and when we consider offering prophylaxis in patients with nonsevere hemophilia. Our proposals can be the basis for discussions in the community about the assessment of SBPT and the initiation of prophylaxis in patients with nonsevere hemophilia without inhibitors.<\/jats:p>","DOI":"10.1055\/a-2411-7416","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:16:11Z","timestamp":1731456971000},"source":"Crossref","is-referenced-by-count":2,"title":["Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia"],"prefix":"10.1055","author":[{"given":"Christian","family":"Pfrepper","sequence":"additional","affiliation":[{"name":"Division of Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Escuriola","family":"Ettingshausen","sequence":"additional","affiliation":[{"name":"Hemophilia Centre Rhein Main (HZRM), Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Klamroth","sequence":"additional","affiliation":[{"name":"Vivantes Klinikum im Friedrichshain, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Pediatric Thrombosis and Hemostasis Center, Pediatric Hemophilia Center, Dr. von Hauner Children's Hospital, LMU Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref2","first-page":"535","article-title":"Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management","volume":"16","author":"G Benson","year":"2018","journal-title":"Blood Transfus"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/jth.14315","article-title":"The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH","volume":"16","author":"M Makris","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/jcm12041368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"G Castaman","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"V S Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/HS9.0000000000000286","article-title":"Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA Consensus Report","volume":"3","author":"F Rodeghiero","year":"2019","journal-title":"HemaSphere"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"F Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/jth.14257","article-title":"The predictive value of factor VIII\/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH","volume":"16","author":"M E Mancuso","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"100062","DOI":"10.1016\/j.rpth.2023.100062","article-title":"In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype","volume":"7","author":"M JA Verhagen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"P Agosti","year":"2023","journal-title":"Blood Adv"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtha.2023.09.029","article-title":"Patients with moderate hemophilia A and B with a severe bleeding phenotype have an increased burden of disease","volume":"22","author":"M JA Verhagen","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jtha.2023.03.016","article-title":"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets","volume":"21","author":"J Thachil","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.rpth.2023.100047","article-title":"Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status","volume":"7","author":"J Rejt\u0151","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"C N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.14676","article-title":"Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: a review of the literature","volume":"29","author":"A Iorio","year":"2023","journal-title":"Haemophilia"},{"issue":"14","key":"ref16","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"F R Kloosterman","year":"2022","journal-title":"Blood Adv"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/jcm11071969","article-title":"Intracranial haemorrhage in haemophilia patients is still an open issue: the final results of the Italian EMO","volume":"11","author":"E Zanon","year":"2022","journal-title":"J Clin Med"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jth.15676","article-title":"Joint status of patients with nonsevere hemophilia A","volume":"20","author":"A F Zwagemaker","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?","volume":"27","author":"P W Collins","year":"2021","journal-title":"Haemophilia"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/hae.13628","article-title":"Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score","volume":"25","author":"V Jim\u00e9nez-Yuste","year":"2019","journal-title":"Haemophilia"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.12.023","article-title":"Choice of factor VIII\/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15\u201325)","volume":"151","author":"S Meunier","year":"2017","journal-title":"Thromb Res"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hae.13117","article-title":"Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia","volume":"23","author":"C Y Chang","year":"2017","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jth.12248","article-title":"Bleeders, bleeding rates, and bleeding score","volume":"11","author":"A Tosetto","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12185-013-1341-9","article-title":"Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A","volume":"97","author":"H Inaba","year":"2013","journal-title":"Int J Hematol"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2516.2011.02539.x","article-title":"Clinical severity of haemophilia A: does the classification of the 1950s still stand?","volume":"17","author":"I E Den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2516.2009.02109.x","article-title":"Assessment of the progression of haemophilic arthropathy in children","volume":"16","author":"H Pergantou","year":"2010","journal-title":"Haemophilia"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2516.2008.01837.x","article-title":"Clinical outcome of moderate haemophilia compared with severe and mild haemophilia","volume":"15","author":"I E den Uijl","year":"2009","journal-title":"Haemophilia"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1538-7836.2008.03001.x","article-title":"Validation of a composite score for clinical severity of hemophilia","volume":"6","author":"S Schulman","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1538-7836.2007.02861.x","article-title":"Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype","volume":"6","author":"M Trossa\u00ebrt","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.14114","article-title":"Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - the MoHem study","volume":"26","author":"R J M\u00e5seide","year":"2020","journal-title":"Haemophilia"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study","volume":"25","author":"M J Scott","year":"2019","journal-title":"Haemophilia"},{"key":"ref32","first-page":"s330","article-title":"Outcome in moderate haemophilia","volume":"12","author":"I den Uijl","year":"2014","journal-title":"Blood Transfus"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance","volume":"7","author":"R EG Schutgens","year":"2023","journal-title":"HemaSphere"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/hematology.2022000387","article-title":"Perioperative hemostasis for patients with hemophilia","volume":"2022","author":"J N Poston","year":"2022","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1576\/toag.6.2.88.26983","article-title":"Quantification of menstrual blood loss","author":"G Warrilow","year":"2004","journal-title":"Obstet Gynaecol"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/rth2.12314","article-title":"Hemophilia management: huge impact of a tiny difference","volume":"4","author":"F Kloosterman","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2022.11.015","article-title":"Very high risk of intracranial hemorrhage and severe outcomes in adult patients with mild hemophilia: sub-analysis of the EMO","volume":"221","author":"S Pasca","year":"2023","journal-title":"Thromb Res"},{"issue":"9371","key":"ref40","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"P H Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0033-1354422","article-title":"Arthropathy in patients with moderate hemophilia A: a systematic review of the literature","volume":"39","author":"M N Di Minno","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref42","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"R Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjh.17919","article-title":"Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres","volume":"196","author":"M ND Di Minno","year":"2022","journal-title":"Br J Haematol"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B","volume":"190","author":"R Rayment","year":"2020","journal-title":"Br J Haematol"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"I E den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"16","key":"ref47","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"J M Soucie","year":"2018","journal-title":"Blood Adv"},{"issue":"08","key":"ref48","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3324\/haematol.2019.242735","article-title":"Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies","volume":"105","author":"F Peyvandi","year":"2020","journal-title":"Haematologica"},{"issue":"77","key":"ref49","first-page":"77","article-title":"Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B","volume":"36","author":"A Ahlberg","year":"1965","journal-title":"Acta Orthop Scand Suppl"},{"issue":"13","key":"ref50","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.2020009603","article-title":"Prophylaxis in hemophilia: how much is enough?","volume":"137","author":"C L Kempton","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2516.2008.01899.x","article-title":"Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre","volume":"15","author":"A L Poulsen","year":"2009","journal-title":"Haemophilia"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2006.06402.x","article-title":"In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results","volume":"136","author":"S E Rodgers","year":"2007","journal-title":"Br J Haematol"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3026(23)00033-9","article-title":"Emicizumab for non-severe haemophilia A","volume":"10","author":"M Makris","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2411-7416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:16:22Z","timestamp":1731456982000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2411-7416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1055\/a-2411-7416","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}